Opinion|Videos|October 2, 2024
How Type 2 Inflammation Influences Treatment Choices
Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.
Advertisement
Episodes in this series
- In your experience, how does knowing a patient has type 2 inflammation influence the choice in treatment?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
5